OUR DEVELOPMENT PORTFOLIO

Updated April 2020

Cardiovascular diseases
Diabetes
Cancer
Immune-Inflammatory diseases
Neuropsychiatric diseases

Phase 1

Haematological malignancies

Mcl1 inhibitor

Solid tumors

Mcl1 inhibitor

Haematological malignancies

Bcl2 inhibitor

Haematological malignancies

UCART 19

Cancer

Anti PD1xAnti TIM3

Cancer

Anti PD1xAnti LAG3

Cancer

Anti PD1xAnti LAG3xAnti TIM3

Haematological malignancies

Cart 19

Sjögren disease/UC

Anti IL7R

Phase 2

Venous leg ulcers

Ischemic stroke

TAFIa inhibitor

Osteoarthritis

ADAMTS-5 inhibitor

Phase 3

Colorectal cancer, 1st line

Trifluridine/Tipiracil

Colorectal cancer, 3rd line Combo Bevac

Trifluridine/Tipiracil

Chronic heart failure

Omecamtiv mecarbil

Type 2 diabetes

Exenatide implant

Autism

Bumetanide